Teva whistleblower says SEC is taking too long to determine award

A purported whistleblower in Teva Pharmaceutical’s FCPA case says the SEC has “unreasonably delayed” ruling on whether his tip should be granted an award.

Get unlimited access to all Global Investigations Review content